Detalles de la búsqueda
1.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol;
23(4): 540-552, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358455
2.
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
Br J Cancer;
125(11): 1561-1569, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599295
3.
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
J Transl Med;
19(1): 232, 2021 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34059094
4.
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Invest New Drugs;
38(5): 1588-1597, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32246224
5.
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Lancet Oncol;
20(12): 1702-1709, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31628016
6.
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Eur J Cancer;
202: 113973, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447379
7.
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Aliment Pharmacol Ther;
59(7): 865-876, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38327102
8.
Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.
Curr Opin Oncol;
25(2): 115-20, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23262832
9.
Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.
Cancers (Basel);
15(24)2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38136333
10.
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
J Immunother Cancer;
11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37661097
11.
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.
Cancers (Basel);
15(14)2023 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37509274
12.
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Mol Oncol;
17(5): 779-791, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36852704
13.
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
J Immunother Cancer;
10(4)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477861
14.
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.
Front Med (Lausanne);
9: 875974, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35707528
15.
Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients.
Cancers (Basel);
13(13)2021 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34209601
16.
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.
Sci Rep;
11(1): 21357, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34725384
17.
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Mol Oncol;
15(4): 887-900, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33342055
18.
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Clin Lung Cancer;
21(5): 428-436.e2, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32461037
19.
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Clin Cancer Res;
14(12): 3867-74, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18559607
20.
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
J Clin Oncol;
37(10): 790-798, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785827